Patent · US Active

Combination PIV3/hMPV RNA vaccines

US10064934B2 · kind B2 · utility

95Cited by
30References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 11, 2017
Grant dateSep 4, 2018
Priority date—
Expiry dateAug 11, 2037

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.